123 results on '"Clisant, S"'
Search Results
2. LBA-04 The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results
3. French version of the Functional Assessment of Cancer Therapy–Cognitive Function (FACT-Cog) version 3
4. Prognostic factors for adult sarcomas of head and neck
5. Additional direct medical costs associated with nosocomial infections after head and neck cancer surgery: a hospital-perspective analysis
6. Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS)
7. Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: Phase III EPIC trial
8. Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS)
9. Circulating vascular endothelial growth factor (VEGF) as prognostic factor of progression-free survival in patients with advanced chordoma receiving sorafenib: An analysis from a phase II trial of the French Sarcoma Group (GSF/GETO)
10. LBA-04The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results
11. Participation in randomised clinical trials is linked to emotion regulation strategies
12. 2294 Growth modulation index (GMI) to assess salvage chemotherapy benefit after FOLFIRINOX progression in metastatic pancreatic adenocarcinoma
13. 2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study
14. 901 Reporting adverse events (AEs) in cancer surgery randomized trial: A systemic analysis of published trials in oesogastric (OG) and gynecological (GY) cancer patients
15. 780TiP - Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: Phase III EPIC trial
16. Choi Vs. Recist Assessment of Tumor Response in a Retrospective Analysis of Patients (Pts) Receiving Trabectedin (T) for Advanced Soft Tissue Sarcomas (Asts)
17. Rebecca: a Large Cohort Study of Regorafenib (Reg) in the Real-Life Setting in Patients (Pts) Previously Treated for Metastatic Colorectal Cancer (Mcrc)
18. Benefit of Maintenance Therapy with Trabectedin (T) Beyond the 6 First Cycles: Results of a Prospective Randomized Phase Ii Trial Comparing Interruption Vs. Continuation of T in Patients (Pts) with Advanced Soft Tissue Sarcoma (Asts): an Update
19. Determinants of patient delay in doctor consultation in head and neck cancers (Protocol DEREDIA)
20. 1405PD - Circulating vascular endothelial growth factor (VEGF) as prognostic factor of progression-free survival in patients with advanced chordoma receiving sorafenib: An analysis from a phase II trial of the French Sarcoma Group (GSF/GETO)
21. 1406P - Update of the T-DIS randomized phase II trial: Trabectedin rechallenge versus continuation in patients (pts) with advanced soft tissue sarcoma (ASTS)
22. A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
23. Abstract P2-13-10: Prospective randomized and multicentric evaluation of cognition in menopausal breast cancer patients receiving adjuvant hormonotherapy: a phase III study (Preliminary results)
24. Vulnerability assessment of the elderly cancer patients: Concordance between screening tests and subjective physician evaluation
25. 1306 POSTER Accuracy of Clinical Judgment of Progressive Disease in Phase II Trials
26. Patients (pts) accessible to interview in palliative care unit: Analysis of inherent biases.
27. Adult sarcomas: Incidence and initial management before implantation of regional sarcoma committee in northern France.
28. Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care
29. Is the maximal tolerated dose still the best primary endpoint? Analysis of 288 dose-seeking phase I trials
30. Determinants of accrual period of time in dose escalating phase I trials
31. Objective measure of patients’ understanding of their role in a randomized trial: A multicenter case-control study
32. Oral metronomic chemotherapy using cyclophosphamide in metastatic patients (pts) after standard treatment: Results of a randomized phase II trial
33. A Canceropole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma
34. Oral metronomic cyclophosphamide (OMC) versus megestrol acetate (MA) among patients with advanced, refractory and progressive solid tumours: A randomized phase II study
35. Prognostic factors for cancer patients with good performance status considered for inclusion in phase I clinical trials
36. P.202 Prognostic significance of hypercalcemia inaerodigestive tract cancers
37. P.78 Cost of wound infection (WI) in major headand neck cancer surgery
38. 1442P - Choi Vs. Recist Assessment of Tumor Response in a Retrospective Analysis of Patients (Pts) Receiving Trabectedin (T) for Advanced Soft Tissue Sarcomas (Asts)
39. 1414O - Benefit of Maintenance Therapy with Trabectedin (T) Beyond the 6 First Cycles: Results of a Prospective Randomized Phase Ii Trial Comparing Interruption Vs. Continuation of T in Patients (Pts) with Advanced Soft Tissue Sarcoma (Asts): an Update
40. 602P - Rebecca: a Large Cohort Study of Regorafenib (Reg) in the Real-Life Setting in Patients (Pts) Previously Treated for Metastatic Colorectal Cancer (Mcrc)
41. Cancer-associated hypercalcemia treated with intravenous diphosphonates: a survival and prognostic factor analysis.
42. Prevention of wound infection in breast cancer surgery with a strategy based on administration of antibiotic prophylaxis in patients at high risk of wound infection occurrence
43. Circulating thrombospondin 1 level as a surrogate marker in patients receiving cyclophosphamide-based metronomic chemotherapy.
44. Leukaemia and myelodysplasia after breast cancer: A national case-control study evaluating the risk associated with anthracyclines and anthracenedione
45. 'Sufficient life expectancy': an amazing inclusion criterion in cancer phase II-III trials.
46. Leukaemia and myelodysplasia after breast cancer: A national case-control study evaluating the risk associated with anthracyclines and anthracenedione
47. Prospective randomized and multicentric evaluation of cognition in menopausal breast cancer patients receiving adjuvant hormonotherapy: a phase III study (Preliminary results).
48. Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial.
49. The ongoing French metastatic breast cancer (MBC) cohort: the example-based methodology of the Epidemiological Strategy and Medical Economics (ESME).
50. Impact of Trabectedin Interruption and Subsequent Rechallenge on Progression in Patients With Advanced Soft Tissue Sarcoma: Long-term Follow-up of the T-DIS trial.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.